These results suggested that co-medication of BAR blockers may be associated with reduced mortality of skin cancer patients, and were supported by subsequent in vitro and in vivo studies which demonstrated the role of BAR in tumor growth and stress-response signaling via SRC activation in cancer cells. The gene discussed is SRC; the disease is skin neoplasm.